Effects of initiation of 3'-azido-3'-deoxythymidine (zidovudine) treatment at different times after infection of rhesus monkeys with simian immunodeficiency virus

DOI: 10.1093/infdis/168.4.825
Journal of Infectious Diseases, 1993, 168, 825-35.

#	Paper	IF	Citations
92	Present status and future prospects for HIV therapies. *Science*, **1993**, 260, 1286-93	33.3	189
91	Effects of U-75875, a peptidomimetic inhibitor of retroviral proteases, on simian immunodeficiency virus infection in rhesus monkeys. *Antimicrobial Agents and Chemotherapy*, **1994**, 38, 1277-83	5.9	26
90	Preexposure prophylaxis with 9-(2-phosphonylmethoxyethyl)adenine against simian immunodeficiency virus infection in macaques. *Journal of Infectious Diseases*, **1994**, 169, 260-6	7	42
89	Donnés de l'expérimentation animale concernant la chimioprophylaxie après exposition au VIH. *Médecine Et Maladies Infectieuses*, **1994**, 24, 1214-1221	4	
88	Comparison of the efficacy of AZT and PMEA treatment against acute SIVmne infection in macaques. *Journal of Medical Primatology*, **1994**, 23, 175-83	0.7	19
87	Passive immunization of macaques against SIV infection. *Journal of Medical Primatology*, **1994**, 23, 164-74	0.7	19
86	Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors. *Proceedings of the National Academy of Sciences of the United States of America*, **1995**, 92, 8210-4	11.5	115
85	Distribution of SIV in lymph nodes of serially sacrificed rhesus monkeys. *AIDS Research and Human Retroviruses*, **1995**, 11, 273-85	1.6	34
84	Zidovudine treatment prolongs survival and decreases virus load in the central nervous system of rhesus macaques infected perinatally with simian immunodeficiency virus. *Journal of Infectious Diseases*, **1995**, 172, 59-69	7	23
83	Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. *Science*, **1995**, 270, 1197-9	33.3	472
82	Infection and AIDS in adult macaques after nontraumatic oral exposure to cell-free SIV. *Science*, **1996**, 272, 1486-9	33.3	135
81	Evidence that high-dosage zidovudine at time of retrovirus exposure reduces antiviral efficacy. *Antimicrobial Agents and Chemotherapy*, **1996**, 40, 2183-6	5.9	4
80	Should PUVA be abandoned?. *New England Journal of Medicine*, **1997**, 336, 1090-1	59.2	34
79	Therapy for bleeding peptic ulcers. *New England Journal of Medicine*, **1997**, 336, 1091-3	59.2	24
78	Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection-drug use. *New England Journal of Medicine*, **1997**, 336, 1097-100	59.2	122
77	Postexposure treatment of HIV. *New England Journal of Medicine*, **1997**, 337, 499-500; author reply 501	59.2	6
76	Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in macaques. *AIDS Research and Human Retroviruses*, **1997**, 13, 707-12	1.6	67

75	Prevention of simian immunodeficiency virus, SIVsm, or HIV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005. *Aids*, **1997**, 11, 157-62	3.5	66
74	Early postinfection antiviral treatment reduces viral load and prevents CD4+ cell decline in HIV type 2-infected macaques. *AIDS Research and Human Retroviruses*, **1997**, 13, 1375-81	1.6	49
73	Animal studies of prophylaxis. *American Journal of Medicine*, **1997**, 102, 39-44	2.4	46
72	Risk of occupational exposure to potentially infectious nonhuman primate materials and to simian immunodeficiency virus. *Journal of Medical Primatology*, **1997**, 26, 233-40	0.7	18
71	Longitudinal analysis of behavioral, neurophysiological, viral and immunological effects of SIV infection in rhesus monkeys. *Journal of Medical Primatology*, **1998**, 27, 104-12	0.7	47
70	Pathogenesis of simian immunodeficiency virus pneumonia: an immunopathological response to virus. *American Journal of Pathology*, **1998**, 153, 1123-30	5.8	29
69	Should preventive antiretroviral treatment be offered following sexual exposure to HIV? The case for. *Sexually Transmitted Infections*, **1998**, 74, 144-5	2.8	5
68	Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques. *AIDS Research and Human Retroviruses* , **1998**, 14, 761-73	1.6	69
67	Cost-effectiveness of post-exposure prophylaxis following sexual exposure to HIV. *Aids*, **1998**, 12, 1067-1078	3.5	42
66	Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. *Journal of Virology*, **1998**, 72, 4265-73	6.6	260
65	Virus threshold determines disease in SIVsmmPBj14-infected macaques. *AIDS Research and Human Retroviruses*, **1999**, 15, 183-94	1.6	6
64	Ethanol Suppression of the Functional State of Polymorphonuclear Leukocytes Obtained From Uninfected and Simian Immunodeficiency Virus Infected Rhesus Macaques. *Alcoholism: Clinical and Experimental Research*, **1999**, 23, 878-884	3.7	22
63	Progress and challenges in therapies for AIDS in nonhuman primate models. *Journal of Medical Primatology*, **1999**, 28, 154-63	0.7	10
62	Weighing the consequence of doing nothing versus those of doing something: post-exposure chemoprophylaxis for occupational exposures to HIV. *Journal of Hospital Infection*, **1999**, 43 Suppl, S225-33	6.9	0
61	SURGEON AND HIV INFECTION: Post Exposure Prophylaxis: Need of the hour. *Medical Journal Armed Forces India*, **2000**, 56, 328-331	1.9	
60	Antiretroviral prophylaxis of health care workers at two urban medical centers. *Journal of Occupational and Environmental Medicine*, **2000**, 42, 1092-100	2	11
59	Nonoccupational HIV postexposure prophylaxis: a new role for the emergency department. *Annals of Emergency Medicine*, **2000**, 36, 366-75	2.1	14
58	In vitro ethanol suppresses alveolar macrophage TNF-alpha during simian immunodeficiency virus infection. *American Journal of Respiratory and Critical Care Medicine*, **2000**, 161, 135-40	10.2	45

57	Re: Emergency Department management of occupational exposures to HIV-infected fluids. *Journal of Emergency Medicine*, **2000**, 18, 121-2	1.5	1
56	La quimioprofilaxis postexposici al virus de la inmunodeficiencia humana en el ni y el adolescente. *Anales De Pediatr*, **2000**, 53, 356-359	0.2	
55	HIV and AIDS in the workplace. *Journal of Occupational and Environmental Medicine*, **2002**, 44, 495-502	2	2
54	Macrophages relate presynaptic and postsynaptic damage in simian immunodeficiency virus encephalitis. *American Journal of Pathology*, **2002**, 160, 927-41	5.8	35
53	Effects of In Vitro Ethanol on Tumor Necrosis Factor-?? Production by Blood Obtained From Simian Immunodeficiency Virus???Infected Rhesus Macaques. *Alcoholism: Clinical and Experimental Research*, **2002**, 26, 527-534	3.7	
52	Combination Antiretroviral Therapies for HIV. **2002**, 83-112		
51	Effects of In Vitro Ethanol on Tumor Necrosis Factor- Production by Blood Obtained From Simian Immunodeficiency Virus nfected Rhesus Macaques. *Alcoholism: Clinical and Experimental Research*, **2002**, 26, 527-534	3.7	9
50	The effect of chronic binge ethanol consumption on the primary stage of SIV infection in rhesus macaques. *Alcoholism: Clinical and Experimental Research*, **2003**, 27, 495-502	3.7	58
49	Clinical practice. Occupational exposure to HIV in health care settings. *New England Journal of Medicine*, **2003**, 348, 826-33	59.2	103
48	Spectrum of manifestations of Mycobacterium tuberculosis infection in primates infected with SIV. *AIDS Research and Human Retroviruses*, **2003**, 19, 585-95	1.6	22
47	[German-Austrian guidelines for postexposure prophylaxis of HIV infection. (May, 2002, update)]. *Deutsche Medizinische Wochenschrift*, **2003**, 128 Suppl 1, S36-50	0	0
46	Postexposure prophylaxis in children and adolescents for nonoccupational exposure to human immunodeficiency virus. *Pediatrics*, **2003**, 111, 1475-89	7.4	85
45	Natural and experimental infection of immunocompromised rhesus macaques (Macaca mulatta) with the microsporidian Enterocytozoon bieneusi genotype D. *Microbes and Infection*, **2004**, 6, 996-1002	9.3	19
44	Simian Retroviruses. **2004**, 195-262		4
43	Viral and immunological factors associated with breast milk transmission of SIV in rhesus macaques. *Retrovirology*, **2004**, 1, 17	3.6	56
42	Hematologic and lymphocyte immunophenotypic reference values for normal rhesus monkey (Macaca mulatta) umbilical cord blood; gravidity may play a role in study design. *Journal of Medical Primatology*, **2005**, 34, 147-53	0.7	3
41	HIV postexposure prophylaxis for pediatric patients. **2005**, 384-410		
40	Alterations in the profile of blood cell types during malaria in previously unexposed primigravid monkeys. *Journal of Infectious Diseases*, **2005**, 191, 1940-52	7	11

39	Development of model infectious disease protocols for fire and EMS personnel. *Prehospital Emergency Care*, **2005**, 9, 326-32	2.8	5
38	In vivo Models of HIV Disease and Control. **2006**,		4
37	Longitudinal analysis of monocyte/macrophage infection in simian immunodeficiency virus-infected, CD8+ T-cell-depleted macaques that develop lentiviral encephalitis. *American Journal of Pathology*, **2006**, 168, 1553-69	5.8	23
36	SIV as a Model for AIDS Pathogenesis Studies. **2006**, 101-119		
35	SIV Infection of Macaques as a Model for AIDS Drug Studies. **2006**, 121-147		
34	HIV postexposure prophylaxis for pediatric patients. 450-470		
33	Chronic binge ethanol consumption accelerates progression of simian immunodeficiency virus disease. *Alcoholism: Clinical and Experimental Research*, **2006**, 30, 1781-90	3.7	64
32	DNA immunization in combination with effective antiretroviral drug therapy controls viral rebound and prevents simian AIDS after treatment is discontinued. *Virology*, **2006**, 348, 200-15	3.6	28
31	Effects of monotherapy with (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA) on the evolution of a primary Simian immunodeficiency virus (SIV) isolate. *Virology*, **2006**, 354, 116-31	3.6	5
30	Human T cell leukemia virus type 1 up-regulation after simian immunodeficiency virus-1 coinfection in the nonhuman primate. *Journal of Infectious Diseases*, **2007**, 195, 562-71	7	11
29	Significant virus replication in Langerhans cells following application of HIV to abraded skin: relevance to occupational transmission of HIV. *Journal of Immunology*, **2008**, 180, 3297-304	5.3	43
28	Systemic and brain macrophage infections in relation to the development of simian immunodeficiency virus encephalitis. *Journal of Virology*, **2008**, 82, 5031-42	6.6	10
27	Presentation of child sexual abuse cases to Queen Elizabeth Central Hospital following the establishment of an HIV post-exposure prophylaxis programme. *Malawi Medical Journal*, **2009**, 21, 54-8	1.2	7
26	HIV and AIDS in the workplace. *Journal of Occupational and Environmental Medicine*, **2009**, 51, 243-50	2	1
25	[Post-exposure prophylaxis of HIV infection. German-Austrian recommendations, update September 2007]. *Deutsche Medizinische Wochenschrift*, **2009**, 134 Suppl 1, S16-33	0	5
24	Prevention of vaginal simian immunodeficiency virus transmission in macaques by postexposure prophylaxis with zidovudine, lamivudine and indinavir. *Aids*, **2009**, 23, 447-54	3.5	22
23	Evaluation of antiretrovirals in animal models of HIV infection. *Antiviral Research*, **2010**, 85, 159-75	10.8	42
22	Therapeutic DNA vaccine induces broad T cell responses in the gut and sustained protection from viral rebound and AIDS in SIV-infected rhesus macaques. *PLoS ONE*, **2012**, 7, e33715	3.7	34

21	The effects of chronic binge alcohol on the genital microenvironment of simian immunodeficiency virus-infected female rhesus macaques. *AIDS Research and Human Retroviruses*, **2014**, 30, 783-91	1.6	11
20	Novel immunological strategies for HIV-1 eradication. *Journal of Virus Eradication*, **2015**, 1, 232-236	2.8	4
19	Efficacy of HIV Postexposure Prophylaxis: Systematic Review and Meta-analysis of Nonhuman Primate Studies. *Clinical Infectious Diseases*, **2015**, 60 Suppl 3, S165-9	11.6	35
18	Preferential Destruction of Interstitial Macrophages over Alveolar Macrophages as a Cause of Pulmonary Disease in Simian Immunodeficiency Virus-Infected Rhesus Macaques. *Journal of Immunology*, **2015**, 195, 4884-91	5.3	23
17	Marked Enteropathy in an Accelerated Macaque Model of AIDS. *American Journal of Pathology*, **2017**, 187, 589-604	5.8	
16	Tenofovir DF/emtricitabine/rilpivirine as HIV post-exposure prophylaxis: results from a multicentre prospective study. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 1021-1027	5.1	6
15	Knowledge, Attitude, and Practice of Postexposure Prophylaxis against HIV Infection among Healthcare Workers in Hiwot Fana Specialized University Hospital, Eastern Ethiopia. *AIDS Research and Treatment*, **2019**, 2019, 7947086	2.3	8
14	Mechanisms of Retroviral Resistance. *Updates in Clinical Dermatology*, **2021**, 75-90	0.2	0
13	The Simian Retroviruses SIV and SRV. **1994**, 133-276		27
12	The replicative capacity of rhesus macaque peripheral blood mononuclear cells for simian immunodeficiency virus in vitro is predictive of the rate of progression to AIDS in vivo. *Journal of General Virology*, **2000**, 81, 2441-2449	4.9	31
11	Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus. *Journal of Virology*, **1995**, 69, 2737-44	6.6	135
10	Pathogenesis of simian immunodeficiency virus encephalitis: viral determinants of neurovirulence. *Journal of Virology*, **1997**, 71, 6055-60	6.6	126
9	Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection. *Journal of Virology*, **1999**, 73, 4829-39	6.6	103
8	Universal Precautions and Post-exposure Prophylaxis for HIV. **2002**, 891-898		
7	Animal Models of HIV Infection. **1999**, 1061-1068		
6	The Link Between HIV Knowledge and Prophylaxis to Health Professionals. *Open Access Macedonian Journal of Medical Sciences*, **2019**, 7, 1396-1400	1	
5	Prevention of HIV Infection. **2020**, 1-29		
4	Pathogenesis of SIV encephalitis. Selection and replication of neurovirulent SIV. *American Journal of Pathology*, **1997**, 151, 793-803	5.8	106

3	Novel immunological strategies for HIV-1 eradication. *Journal of Virus Eradication*, **2015**, 1, 232-6	2.8	3
2	Selective Induction of Protective MHC Class I-Restricted CTL in the Intestinal Lamina Propria of Rhesus Monkeys by Transient SIV Infection of the Colonic Mucosa. **1999**, 162, 540-549		13
1	An open-label evaluation of safety and tolerability of coformulated bictegravir/emtricitabine/tenofovir alafenamide for post-exposure prophylaxis following potential exposure to human immunodeficiency virus-1. Publish Ahead of Print,		0